Drugs / CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04620681 | Jan 2021 → Jul 2024 | acute myeloid leukemia, myelodysplastic syndrome | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04620681 ↗ |
| Known as | NE-DLI | “This study is attempting to design a therapy called "non-engrafting, CD8 depleted donor lymphocyte infusion" or "NE-DLI" as a treatment for these diseases.” NCT04620681 ↗ |
| Known as | non-engrafting, CD8 depleted donor lymphocyte infusion | “This study is attempting to design a therapy called "non-engrafting, CD8 depleted donor lymphocyte infusion" or "NE-DLI" as a treatment for these diseases.” NCT04620681 ↗ |
| Modality | Cell therapy | “Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent” NCT04620681 ↗ |